Patents Assigned to NHS Blood and Transplant
-
Patent number: 9951350Abstract: The present invention provides a method of preparing adult red blood cells from stem cells in vitro using certain transcription factors for use in medicine, transfusions and transplants. The invention also provides blood compositions with cells prepared by the method.Type: GrantFiled: January 11, 2013Date of Patent: April 24, 2018Assignee: NHS Blood & TransplantInventors: Jan Frayne, David Anstee
-
Publication number: 20140377237Abstract: The present invention provides a method of preparing adult red blood cells from stem cells in vitro using certain transcription factors for use in medicine, transfusions and transplants. The invention also provides blood compositions with cells prepared by the method.Type: ApplicationFiled: January 11, 2013Publication date: December 25, 2014Applicant: NHS Blood & TransplantInventors: Jan Frayne, David Anstee
-
Patent number: 8906366Abstract: Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate.Type: GrantFiled: May 29, 2008Date of Patent: December 9, 2014Assignee: NHS Blood and TransplantInventors: Joanne Lloyd, Peter Feldman
-
Publication number: 20130108594Abstract: The invention provides a method for determining the angiogenic signature of a cell or tissue sample and methods for predicting efficacy of angiogenic therapy, for preparing a predictive model for predicting angiogenic potential, for identifying an agent for use in angiotherapy and therapeutic agents and applications.Type: ApplicationFiled: April 28, 2011Publication date: May 2, 2013Applicant: NHS BLOOD & TRANSPLANTInventors: Enca Martin-Rendon, Suzanne Watt
-
Publication number: 20110021418Abstract: Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both an antioxidant and anti-inflammatory component, such as for hemolytic disease. Material enriched for alpha-2 chain Hp polymeric forms, made for example from Cohn fraction IV precipitate, will be more suitable for treatment of diseases where an angiogenic, and/or inflammatory affect, and/or limited extravasation is desirable.Type: ApplicationFiled: September 20, 2010Publication date: January 27, 2011Applicant: NHS BLOOD AND TRANSPLANTInventors: JOAN DALTON, ADRIAN PODMORE
-
Patent number: 7816495Abstract: The present invention relates to processes for the purification of fibrinogen, and to readily solubilised fibrinogen preparations.Type: GrantFiled: July 7, 2003Date of Patent: October 19, 2010Assignee: NHS Blood and TransplantInventors: Sarah Kingsland, Robert Clemmitt, David Evans, Peter Feldman
-
Publication number: 20090292114Abstract: The invention relates to methods for the isolation of AAT from solutions containing albumin and AAT using at least two separate metal chelate chromatography steps. The product may be further purified and/or subjected to one or more virus inactivation or reduction steps. The isolated AAT may then be formulated for pharmaceutical use.Type: ApplicationFiled: November 29, 2006Publication date: November 26, 2009Applicant: NHS Blood and TransplantInventors: Peter Kumpalume, Adrian Podmore, Joan Dalton
-
Publication number: 20090281282Abstract: The invention provides a method for the isolation of haptoglobin from a sample comprising Cohn fraction V, wherein said method comprises anion exchange chromatography of said sample. The product may be further purified and/or subjected to one or more virus inactivation or reduction steps. The isolated haptoglobin may then be formulated for pharmaceutical use.Type: ApplicationFiled: October 19, 2005Publication date: November 12, 2009Applicant: NHS BLOOD AND TRANSPLANTInventors: Joan Dalton, Adrian Podmore, Peter Kumpalume
-
Publication number: 20080293623Abstract: Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both an antioxidant and anti-inflammatory component, such as for hemolytic disease. Material enriched for alpha-2 chain Hp polymeric forms, made for example from Cohn fraction IV precipitate, will be more suitable for treatment of diseases where an angiogenic, and/or inflammatory affect, and/or limited extravasation is desirable.Type: ApplicationFiled: April 30, 2008Publication date: November 27, 2008Applicant: NHS Blood and TransplantInventors: Joan Dalton, Adrian Podmore
-
Patent number: D648944Type: GrantFiled: April 28, 2011Date of Patent: November 22, 2011Assignee: NHS Blood and TransplantInventors: Bruce James Renfrew, Kenneth Poberezny, William James Williamson, Shaun Melvyn Phillips
-
Patent number: D649318Type: GrantFiled: April 28, 2011Date of Patent: November 22, 2011Assignee: NHS Blood and TransplantInventors: Bruce James Renfrew, Kenneth Poberezny, William James Williamson, Shaun Melvyn Phillips
-
Patent number: D649319Type: GrantFiled: April 28, 2011Date of Patent: November 22, 2011Assignee: NHS Blood and TransplantInventors: Bruce James Renfrew, Kenneth Poberezny, William James Williamson, Shaun Melvyn Phillips
-
Patent number: D649320Type: GrantFiled: April 28, 2011Date of Patent: November 22, 2011Assignee: NHS Blood and TransplantInventors: Bruce James Renfrew, Kenneth Poberezny, William James Williamson, Shaun Melvyn Phillips